Literature DB >> 33707839

Conditioning Regimens for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Stem Cell Transplantation: BEAM Versus High Dose ICE.

Ahmet Kursad Gunes1, Simten Dagdas2, Funda Ceran1, Mehmet Ali Ucar3, Mesude Falay4,5, Cenk Sunu6, Meltem Ayli7, Nurullah Zengin8, Gulsum Ozet1,9.   

Abstract

There are different drug combinations and conditioning regimens in lymphoma transplants. However, no randomized data is available to demonstrate the superiority of any regimen and the optimal choice is unknown. In this analysis, we compared the efficacy, toxicity and the survival outcomes of the BEAM and the high dose ICE (hdICE) conditioning regimens in relapsed NHL and relapsed/refractory Hodgkin Lymphoma patients undergoing auto-SCT. 83 patients with relapsed/refractory HL or relapsed NHL who were treated with Auto-SCT between 2006 and 2016, were analyzed retrospectively. 52 patients (62.7%) received BEAM, while 31 patients (37.3%) received hdICE. Between two groups there is no significant difference in age, gender, diagnosis, disease stage, chemosensitivity, ECOG performance status, time from diagnosis to transplant, salvage regimens and previous lines of chemotherapy. After a median of 59-month follow-up, PFS and OS rates of both groups were similar (5-year PFS was 51.6% in BEAM group, 48.8% in hdICE group, p = 0.71; 5-year OS was 58% in BEAM group, 54.8% in hdICE group, p = 0.93). The median neutrophil (11 vs. 10 days, p = 0.06) and platelet engraftment (13 vs. 11 days, p = 0.01) was faster and demand of transfusions were lesser in hdICE group (p = 0.03). However, severe renal toxicity was significantly higher in hdICE group in our study (p = 0.01). hdICE conditioning regimen may be used as an alternative to BEAM, with similar survival outcomes and toxicity profile, especially transplant centers that experience some difficulties in the availability of the carmustine. © Indian Society of Hematology and Blood Transfusion 2020.

Entities:  

Keywords:  Autologous stem cell transplantation; BEAM; Conditioning regimens; High dose ICE; Lymphoma

Year:  2020        PMID: 33707839      PMCID: PMC7900376          DOI: 10.1007/s12288-020-01317-5

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  18 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation.

Authors:  Noemí Puig; Javier de la Rubia; María J Remigia; Isidro Jarque; Guillermo Martín; Luca Cupelli; Guillermo F Sanz; Ignacio Lorenzo; Jaime Sanz; Jesús A Martínez; Carmen Jiménez; Miguel A Sanz
Journal:  Leuk Lymphoma       Date:  2006-08

3.  Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.

Authors:  A Sureda; R Arranz; A Iriondo; E Carreras; J J Lahuerta; J García-Conde; I Jarque; M D Caballero; C Ferrà; A López; J García-Laraña; R Cabrera; D Carrera; M D Ruiz-Romero; A León; J Rifón; J Díaz-Mediavilla; R Mataix; M Morey; J M Moraleda; A Altés; A López-Guillermo; J de la Serna; J M Fernández-Rañada; J Sierra; E Conde
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

4.  Impact of high-dose salvage therapy (BEAM) on overall survival in younger patients with advanced large-cell lymphomas entered into BNLI trials.

Authors:  D C Linch; B Vaughan Hudson; L Anderson; G Vaughan Hudson
Journal:  Ann Oncol       Date:  1997       Impact factor: 32.976

5.  Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.

Authors:  Yi-Bin Chen; Andrew A Lane; Brent Logan; Xiaochun Zhu; Görgün Akpek; Mahmoud Aljurf; Andrew Artz; Christopher N Bredeson; Kenneth R Cooke; Vincent T Ho; Hillard M Lazarus; Richard Olsson; Wael Saber; Philip McCarthy; Marcelo C Pasquini
Journal:  Biol Blood Marrow Transplant       Date:  2015-02-14       Impact factor: 5.742

6.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

Authors:  D C Linch; D Winfield; A H Goldstone; D Moir; B Hancock; A McMillan; R Chopra; D Milligan; G V Hudson
Journal:  Lancet       Date:  1993-04-24       Impact factor: 79.321

7.  Regimen-related toxicity in patients undergoing bone marrow transplantation.

Authors:  S I Bearman; F R Appelbaum; C D Buckner; F B Petersen; L D Fisher; R A Clift; E D Thomas
Journal:  J Clin Oncol       Date:  1988-10       Impact factor: 44.544

8.  Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity.

Authors:  Youwu Shi; Peng Liu; Shengyu Zhou; Jianliang Yang; Xiaohong Han; Xiaohui He; Changgong Zhang; Lin Gui; Yan Qin; Sheng Yang; Liya Zhao; Jiarui Yao; Bo Jia; Shuxiang Zhang; Yan Sun; Yuankai Shi
Journal:  Asia Pac J Clin Oncol       Date:  2017-01-19       Impact factor: 2.601

9.  Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.

Authors:  K K Fields; G J Elfenbein; H M Lazarus; B W Cooper; J B Perkins; R J Creger; O F Ballester; J H Hiemenz; W E Janssen; P E Zorsky
Journal:  J Clin Oncol       Date:  1995-02       Impact factor: 44.544

10.  BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.

Authors:  W Mills; R Chopra; A McMillan; R Pearce; D C Linch; A H Goldstone
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.